Indication

Epithelial ovarian cancer with BRCA mutation

Epithelial ovarian cancer with a *BRCA* mutation refers to a malignant neoplasm arising from the epithelial surface of the ovary, fallopian tube, or primary peritoneum in patients harboring deleterious germline or somatic mutations in the *BRCA1* or *BRCA2* tumor suppressor genes. Read more about Epithelial ovarian cancer with BRCA mutation

6 drugs 6 manufacturers

Advertisement

Drugs that treat it

Common Epithelial ovarian cancer with BRCA mutation therapies.

Showing 1–6 of 6 drugs

LYNPARZA (olaparib)

ANTINEOPLASTIC-POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR·EPITHELIAL OVARIAN CANCER·+5
AstraZeneca Pharmaceuticals

ZEJULA (niraparib tosylate)

ANTINEOPLASTIC-POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR·EPITHELIAL OVARIAN CANCER WITH BRCA MUTATION·+1
GSK

RUBRACA (rucaparib camsylate)

ANTINEOPLASTIC-POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR·EPITHELIAL OVARIAN CANCER WITH BRCA MUTATION·+1
ZR PHARMA& GMBH
Filter & compare in the drug finder →Opens the drug finder with Epithelial ovarian cancer with BRCA mutation preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Epithelial ovarian cancer with BRCA mutation.

Epithelial ovarian cancer with a *BRCA* mutation refers to a malignant neoplasm arising from the epithelial surface of the ovary, fallopian tube, or primary peritoneum in patients harboring deleterious germline or somatic mutations in the *BRCA1* or *BRCA2* tumor suppressor genes.

This clinical biomarker subgroup most commonly presents in adult women as high-grade serous carcinoma, typically manifesting at advanced stages with peritoneal dissemination, ascites, and abdominal pelvic symptoms.

Pathophysiologically, the loss of functional BRCA protein impairs homologous recombination repair of double-strand DNA breaks, resulting in genomic instability that drives malignant transformation while simultaneously conferring increased cellular vulnerability to DNA-damaging interventions.

Consequently, this molecular subtype is clinically distinguished by heightened initial responsiveness to platinum-based chemotherapies and targeted sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors via synthetic lethality.

Personalize your experience

Follow Epithelial ovarian cancer with BRCA mutation and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it